Federal Bill Would Grant Botanical Drugs 12 Years of Market Exclusivity

H.R. 10150 would block competing applications that rely on a qualifying FDA-approved botanical drug for 12 years, a framework that could apply to some complex cannabis-derived medicines but not necessarily highly purified compounds. Cannabis pharmaceutical developers and investors should track the bill because a longer exclusivity period could materially change research financing, intellectual-property strategy and partnership economics.